Safety and Efficacy of Human Muse Cell-Based Product for Acute Myocardial Infarction in a First-in-Human Trial

• Published in: Circulation Journal Vol. 84; no. 7; pp. 1189 - 1192
• Main Authors: Noda, Toshiyuki, Nishigaki, Kazuhiko, Minatoguchi, Shinya
• Format: Journal Article
• Language: English
• Published: Japan The Japanese Circulation Society 25.06.2020
• Subjects: Acute myocardial infarction; Aged; Cell Lineage; Female; Humans; Male; Middle Aged; Muse cell-based product; Myocardium - pathology; Phenotype; Pluripotent Stem Cells - metabolism; Pluripotent Stem Cells - transplantation; Recovery of Function; Regeneration; Safety; ST Elevation Myocardial Infarction - pathology; ST Elevation Myocardial Infarction - physiopathology; ST Elevation Myocardial Infarction - surgery; Stroke Volume; Time Factors; Treatment Outcome; Ventricular Function, Left; Acute myocardial infarction; Muse cell-based product; Safety
• ISSN: 1346-9843; 1347-4820
• DOI: 10.1253/circj.CJ-20-0307

Background:Because ST-elevation myocardial infarction (STEMI) extensively damages the heart, regenerative therapy with pluripotent stem cells such as multilineage-differentiating stress enduring (Muse) cells is required.Methods and Results:In a first-in-human study, 3 STEMI patients with a left ventricular ejection fraction (LVEF) ≤45% after successful percutaneous coronary intervention received intravenously 1.5×107cells of a human Muse cell-based product, CL2020. The safety and efficacy on LVEF and wall motion score index (WMSI) were evaluated for 12 weeks. No adverse drug reaction was noted. LVEF and WMSI were markedly improved.Conclusions:The first-in-human intravenous administration of CL2020 was safe and markedly improved LV function in STEMI patients.